426 related articles for article (PubMed ID: 38074313)
1. Noninvasive Vagal Nerve Stimulation for Opioid Use Disorder.
Bremner JD; Gazi AH; Lambert TP; Nawar A; Harrison AB; Welsh JW; Vaccarino V; Walton KM; Jaquemet N; Mermin-Bunnell K; Mesfin H; Gray TA; Ross K; Saks G; Tomic N; Affadzi D; Bikson M; Shah AJ; Dunn KE; Giordano NA; Inan OT
Ann Depress Anxiety; 2023; 10(1):. PubMed ID: 38074313
[TBL] [Abstract][Full Text] [Related]
2. Transcutaneous cervical vagus nerve stimulation reduces behavioral and physiological manifestations of withdrawal in patients with opioid use disorder: A double-blind, randomized, sham-controlled pilot study.
Gazi AH; Harrison AB; Lambert TP; Obideen M; Alavi P; Murrah N; Shallenberger L; Driggers EG; Ortega RA; Washington BP; Walton KM; Welsh JW; Vaccarino V; Shah AJ; Tang YL; Gupta R; Back SE; Inan OT; Bremner JD
Brain Stimul; 2022; 15(5):1206-1214. PubMed ID: 36041704
[TBL] [Abstract][Full Text] [Related]
3. Pain is reduced by transcutaneous cervical vagus nerve stimulation and correlated with cardiorespiratory variability measures in the context of opioid withdrawal.
Gazi AH; Harrison AB; Lambert TP; Nawar A; Obideen M; Driggers EG; Vaccarino V; Shah AJ; Rozell CJ; Bikson M; Welsh JW; Inan OT; Bremner JD
Front Pain Res (Lausanne); 2022; 3():1031368. PubMed ID: 36438447
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive brain stimulation modalities for the treatment and prevention of opioid use disorder: a systematic review of the literature.
Young JR; Smani SA; Mischel NA; Kritzer MD; Appelbaum LG; Patkar AA
J Addict Dis; 2020; 38(2):186-199. PubMed ID: 32469286
[TBL] [Abstract][Full Text] [Related]
5. Leveraging Accelerometry as a Prognostic Indicator for Increase in Opioid Withdrawal Symptoms.
Lambert TP; Gazi AH; Harrison AB; Gharehbaghi S; Chan M; Obideen M; Alavi P; Murrah N; Shallenberger L; Driggers EG; Alvarado Ortega R; Washington B; Walton KM; Tang YL; Gupta R; Nye JA; Welsh JW; Vaccarino V; Shah AJ; Bremner JD; Inan OT
Biosensors (Basel); 2022 Oct; 12(11):. PubMed ID: 36354433
[TBL] [Abstract][Full Text] [Related]
6. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management.
Pergolizzi JV; Raffa RB; Rosenblatt MH
J Clin Pharm Ther; 2020 Oct; 45(5):892-903. PubMed ID: 31986228
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review of Noninvasive Brain Stimulation for Opioid Use Disorder.
Ward HB; Mosquera MJ; Suzuki J; Mariano TY
Neuromodulation; 2020 Apr; 23(3):301-311. PubMed ID: 32059080
[TBL] [Abstract][Full Text] [Related]
8. Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research.
Frankeberger J; Jarlenski M; Krans EE; Coulter RWS; Mair C
Matern Child Health J; 2023 Jul; 27(7):1140-1155. PubMed ID: 36840785
[TBL] [Abstract][Full Text] [Related]
9. Variability in opioid use disorder clinical presentations and treatment in the emergency department: A mixed-methods study.
Faude S; Delgado MK; Perrone J; McFadden R; Xiong RA; O'Donnell N; Wood C; Solomon G; Lowenstein M
Am J Emerg Med; 2023 Apr; 66():53-60. PubMed ID: 36706482
[TBL] [Abstract][Full Text] [Related]
10. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research.
Moningka H; Lichenstein S; Worhunsky PD; DeVito EE; Scheinost D; Yip SW
Neuropsychopharmacology; 2019 Jan; 44(2):259-273. PubMed ID: 30283002
[TBL] [Abstract][Full Text] [Related]
11. Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.
Kudrich C; Hurd YL; Salsitz E; Wang AL
Cannabis Cannabinoid Res; 2022 Oct; 7(5):569-581. PubMed ID: 34678050
[No Abstract] [Full Text] [Related]
12. Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders.
Bremner JD; Gurel NZ; Wittbrodt MT; Shandhi MH; Rapaport MH; Nye JA; Pearce BD; Vaccarino V; Shah AJ; Park J; Bikson M; Inan OT
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32916852
[TBL] [Abstract][Full Text] [Related]
13. The role of withdrawal in mesocorticolimbic drug cue reactivity in opioid use disorder.
Shi Z; Jagannathan K; Padley JH; Wang AL; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
Addict Biol; 2021 Jul; 26(4):e12977. PubMed ID: 33098179
[TBL] [Abstract][Full Text] [Related]
14. Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S.
Scott CK; Grella CE; Dennis ML; Carnevale J; LaVallee R
Health Justice; 2022 Dec; 10(1):36. PubMed ID: 36538121
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts.
Wittbrodt MT; Gurel NZ; Nye JA; Ladd S; Shandhi MMH; Huang M; Shah AJ; Pearce BD; Alam ZS; Rapaport MH; Murrah N; Ko YA; Haffer AA; Shallenberger LH; Vaccarino V; Inan OT; Bremner JD
Brain Stimul; 2020; 13(5):1333-1348. PubMed ID: 32659483
[TBL] [Abstract][Full Text] [Related]
16. Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder.
Lee YK; Gold MS; Fuehrlein BS
J Neurol Sci; 2022 Jan; 432():120094. PubMed ID: 34933249
[TBL] [Abstract][Full Text] [Related]
17. Is the Neuroimmune System a Therapeutic Target for Opioid Use Disorder? A Systematic Review.
Toloff K; Woodcock EA
Med Res Arch; 2022 Aug; 10(8):. PubMed ID: 37744743
[TBL] [Abstract][Full Text] [Related]
18. Glial modulators as novel therapeutics for comorbid pain and opioid use disorder.
Schwartz EKC; De Aquino JP; Sofuoglu M
Br J Clin Pharmacol; 2024 May; ():. PubMed ID: 38752593
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
